Skip to content

patrick vermersch

  • MD, PhD
  • 49h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 11267CitationsNumber of citations received by patrick's publications. Updated daily.

Other IDs

Co-authors (2513)

Publications (5)

  • Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): A phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

    • Kapoor R
    • Ho P
    • Campbell N
    • et al.
    N/AReaders
    1Citations
    Get full text
  • Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy

    • Hodel J
    • Bapst B
    • Outteryck O
    • et al.
    N/AReaders
    0Citations
    Get full text
  • Proinflammatory B-cell profile in the early phases of MS predicts an active disease

    • Guerrier T
    • Labalette M
    • Launay D
    • et al.
    N/AReaders
    1Citations
    Get full text
  • Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

    • Kappos L
    • Bar-Or A
    • Cree B
    • et al.
    N/AReaders
    1Citations
    Get full text
  • Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

    • Giovannoni G
    • Soelberg Sorensen P
    • Cook S
    • et al.
    N/AReaders
    1Citations
    Get full text